WEED, Inc.

Company profile

WEED, Inc. is a multinational bio-pharmaceutical and real estate holding company. Its primary focus is Sangre AT, LLC, a wholly owned subsidiary advancing a Cannabis Genomic Study to develop cannabis-derived compounds for human and animal health. The company’s long-term vision includes building and operating laboratories, cultivation centers, and contract research partnerships with universities, governments, and licensed operators, with potential expansion into related products and global licensing and infrastructure.

Core business activities

• Cannabis genomics and breeding research (Sangre AT, LLC)
  • Five-year Cannabis Genomic Study targeting a global genomic classification of Cannabis with a pipeline from extraction to cloning (micro-propagation).
  • Technical objectives: sequence multiple cultivars, perform hybridization to create new stock, conduct genotypic and phenotypic analysis, develop patentable cultivars, and progress market-focused product development for medicinal and biotech applications.
  • Phase 1 progress includes DNA extraction on several strains (pilot work began in 2017–2018) and deployment of proprietary bioinformatics systems for data analysis.
• Intellectual property and technology
  • Exclusive license/transfer discussions with Hebrew University’s Yissum related to lipophilic cannabinoid delivery technologies were terminated before a final license payment; WEED continues collaboration with Professor Elka Touitou for Israeli advisory and clinical work.
  • Sangre and WEED hold trade secrets related to the Cannabis Genomic Study and may pursue patents for promising strains as development advances.
  • Hempirical Genetics, LLC (acquired 2022) provides an asset base of genetics with a seedbank of more than 250 cannabis and hemp strains, including rare landrace varieties such as Panama Red and Acapulco Gold.
• Real estate and infrastructure
  • Long-term real estate assets intended to support research, development, and future manufacturing capabilities.
  • Four Winds of Lake Erie: 44-acre property with lake frontage in Portland, New York; acquired for $477,000 on November 22, 2021.
  • Additional property initiatives include plans tied to a golf course property (Sugar Hill) and other sites for hemp, infused beverages, and related industries.

International and regulatory activities

• WEED Israel Cannabis Ltd.: Engages Professor Elka Touitou for cannabis and hemp research and clinical work in Israel, with potential for human clinical trials under Israeli oversight and ties to Hebrew University researchers.
• WEED Australia Ltd.: Formed for global expansion and deregistered effective November 19, 2025.
• HEMP BioSciences Inc.: Maintains Arizona hemp licenses (cultivation, nursery, processing) through a subsidiary.

Digital assets initiative

In December 2025 WEED entered a strategic partnership with Remergify, Inc. to evaluate a digital asset ecosystem (WEEDCoin and BUDZCoin) intended to address banking and supply chain challenges. Advancement of the initiative will depend on capital availability and the evolving regulatory framework for digital assets.

Key assets and subsidiaries

• Sangre AT, LLC — wholly owned; core vehicle for the Cannabis Genomic Study and downstream breeding and product development.
• Hempirical Genetics, LLC — acquired 2022; proprietary seedbank with over 250 cannabis and hemp strains.
• WEED Israel Cannabis Ltd. — Israeli subsidiary collaborating with Hebrew University researchers; Professor Touitou on the advisory board.
• WEED Australia Ltd. — deregistered November 19, 2025.
• HEMP BioSciences Inc. — Arizona hemp licensing operations (cultivation, nursery, processing).
• Real estate — Four Winds of Lake Erie (44 acres, Portland, NY; acquired November 22, 2021); Sugar Hill golf-course property for hemp/beverage market plans and other property initiatives.

People

As of December 31, 2025, WEED employed two full-time employees:

• Glenn E. Martin
• Nicole M. Breen

Financial and funding context

• The company reports negative cash flows from operations and states it has not generated revenue to date.
• The Cannabis Genomic Study is projected to cost about $15 million; entry into hemp and beverage markets is estimated at about $5 million. Additional working capital will be required.
• Funding strategy includes raising debt or equity, which may dilute current shareholders.

Regulatory and legal context

• Cannabis remains illegal at the federal level in the United States, creating regulatory risk affecting funding, operations, and asset security.
• Research sequencing of the cannabis genome is not federally regulated, while clinical human trials and licensure for medicinal or hemp programs require state licenses (for example, Colorado, Arizona, New York) and compliance with FDA standards for eventual medicinal products.
• Intellectual property protections may be pursued via patents for successful strains; U.S. patent rights could be affected by federal cannabis law.

Market and competitive landscape

• The company focuses on cannabis genomics research and development rather than large-scale cultivation or crude cannabis distribution at this stage.
• Competitors in the broader cannabis space include Canopy Growth, Aurora, Cronos, Trulieve, TerrAscend, Tilray, and others. WEED positions itself on its sequencing approach (combining long reads and short reads), proprietary analytics, and an extensive strain library as differentiators.

Notable disclosures

• The Technology Agreement with Yissum (Hebrew University) was terminated before the final license payment; WEED continues to work with Professor Touitou for Israeli advisory work.
• The company has stated it will develop a marketing plan in later stages once marketable strains are identified.
• WEED is a fully reporting issuer under the Securities Exchange Act of 1934, with securities trading on OTC Markets (OTCQB).

Summary takeaway

WEED, Inc. is positioned as a research-focused cannabis genomics and biotech company with a substantial asset base (seedbank genetics and real estate), a small current workforce, and ongoing plans for multi-year genomic studies, breeding and product development, and potential licensing and manufacturing activities. The company identifies material funding needs and regulatory risks as it advances its genomic and clinical objectives.